Endoplasmic Reticulum Stress and Destruction of Pancreatic Beta Cells in Type 1 Diabetes

0
0
0

Endoplasmic Reticulum Stress and Destruction of Pancreatic Beta Cells in Type 1 Diabetes

Type 1 diabetes (T1D) is an autoimmune disease where the body’s immune system attacks and destroys pancreatic beta cells—the cells that make insulin, the hormone that regulates blood sugar. For decades, scientists have puzzled over why beta cells fail. Today, growing evidence points to a hidden crisis inside these cells: endoplasmic reticulum (ER) stress.

What Is ER Stress?

The ER is a tiny, membrane-bound organelle inside cells that acts like a “protein factory.” For beta cells, its job is critical: folding newly made insulin into the correct 3D shape so it can work. When too many misfolded or unfolded proteins build up in the ER—from things like inflammation, high glucose, or genetic mutations—it triggers ER stress.

To fix this, cells activate the unfolded protein response (UPR), a built-in survival system with three key pathways:

  1. PERK: Hits the “pause button” on protein production to reduce ER overload.
  2. IRE1α: Edits a gene (XBP1) to make a protein that helps fold misfolded insulin.
  3. ATF6: Signals the cell to make more ER “workers” (chaperone proteins) to handle the backlog.

Under mild stress, the UPR saves cells. But if stress becomes chronic or severe, these pathways switch from protective to destructive. They trigger molecules like CHOP (a protein that promotes cell death) and JNK (a kinase that damages cell structures), leading to beta cell apoptosis (programmed cell death).

How ER Stress Leads to Beta Cell Death in T1D

Beta cells are uniquely vulnerable to ER stress because they make so much insulin—up to 1 million molecules per minute. When diabetes-related factors (like viral infections, environmental chemicals, or immune system attacks) disrupt insulin folding, the ER can’t keep up. Here’s what research shows:

In Lab Models

In insulinoma cells (beta cell replicas like INS-1E and Min6), exposure to diabetes-linked cytokines (IL-1β, IFN-γ) turns on ER stress pathways (PERK-eIF2α-CHOP) and kills cells. Silencing CHOP—one of the “death signals”—with gene therapy protects beta cells from high glucose-induced apoptosis.

In Animals

Mice missing key ER genes (like PERK or IRE1α) develop severe diabetes:

  • PERK knockout mice: Are born with high blood sugar and failing beta cells because they can’t pause protein production during stress.
  • NOD mice (a model for T1D): Show ER stress before beta cells are destroyed—proof ER stress is an early step in disease.

In Humans

Mutations in ER-related genes cause rare forms of diabetes:

  • Wolcott-Rallison syndrome: A PERK gene mutation leads to permanent neonatal diabetes (diabetes in infants).
  • INS gene mutations: A single change (L35Q) in the insulin gene disrupts its structure, triggering ER stress and beta cell loss.

The Vicious Cycle: ER Stress, Inflammation, and Autoimmunity

T1D isn’t just about ER stress—it’s about how ER stress interacts with the immune system. Here’s the cycle:

  1. Autoimmune attack: Immune cells (T cells) release cytokines (like TNF-α, IL-1β) that damage beta cells.
  2. ER stress: Cytokines disrupt ER calcium levels and protein folding, increasing stress.
  3. More inflammation: ER stress pathways (like IRE1α-JNK) turn on genes that make more cytokines, worsening the attack.

ER stress also creates neoantigens—proteins that are misfolded or chemically altered (e.g., oxidized insulin). These “broken” proteins look “foreign” to the immune system, triggering T cells to attack beta cells. For example, researchers found that CD4+ T cells from T1D patients recognize an oxidized insulin fragment—something the immune system would ignore if the ER was healthy.

Targeting ER Stress for T1D Treatment

If ER stress drives beta cell death, reducing stress or fixing ER function could stop T1D. Scientists are testing several strategies:

1. Chemical Chaperones

These drugs act like “protein helpers” to fix misfolding. Two leading candidates—tauroursodeoxycholic acid (TUDCA) and 4-phenylbutyric acid (PBA)—are in clinical trials for diabetes. In mice, TUDCA reduces ER stress and protects beta cells.

2. Calcium Stabilizers

ER calcium levels are critical for beta cell survival. Drugs like dantrolene (a calcium channel blocker) keep ER calcium balanced, preventing stress-induced cell death. It’s being studied for Wolfram syndrome, a diabetes-related neurodegenerative disease.

3. Enhancing Protective UPR Pathways

Some drugs boost the “good” parts of the UPR. For example, KIRA6 (an IRE1α inhibitor) preserves beta cell function and lowers blood sugar in diabetic mice by stopping the destructive IRE1α pathway.

4. Natural Compounds

Curcumin (from turmeric) and resveratrol (from grapes) reduce ER stress in lab models. They work by blocking harmful pathways (like JNK) and boosting protective ones (like Nrf2).

Future Questions and Hopes

While ER stress is a key player in T1D, big questions remain:

  • When does the UPR switch from helpful to harmful? Understanding this “tipping point” could let us intervene early.
  • Can ER stress be a biomarker for T1D? Testing blood or urine for ER stress signals might predict who will develop T1D.
  • How do we safely target UPR pathways? The same pathways that kill cells in severe stress also protect them in mild stress—we need drugs that “reset” the balance.

For millions living with T1D, this research offers hope: By fixing the ER’s “protein factory,” we might finally save beta cells and stop the disease.

Zhao-Hui Cao, Zhuan Wu, Cong Hu, Min Zhang, Wu-Zhou Wang, Xiao-Bo Hu
Department of Biochemistry and Molecular Biology, Hengyang Medical College, University of South China, Hengyang, Hunan 421001, China

Originally published in Chinese Medical Journal 2020;133(1).
doi:10.1097/CM9.0000000000000583

Was this helpful?

0 / 0